Collegium Pharma (NASDAQ: COLL) reported Q2 EPS of $1.68, $0.02 better than the analyst estimate of $1.66. Revenue for the quarter came in at $188 million versus the consensus estimate of $182.69 million.

GUIDANCE:

Collegium Pharma sees FY2025 revenue of $745-760 million, versus the consensus of $745.8 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.